Overview

Clinical Trial to Assess the Efficacy and Safety of 'INNOCELL Immuncell-LC' With Temozolomide in Newly Diagnosed Glioblastoma of Korea

Status:
Completed

Trial end date:
2012-10-01

Target enrollment:

Participant gender:

Summary

This clinical study was planned in order to assess the superiority of INNOCELL Corp. "Immuncell-LC" in aspects of therapeutic efficacy and safety when administered with Temozolomide to glioblastoma patients when compared with the control group who did not receive administration of the drug.

Phase:

Phase 3

Details

Lead Sponsor:

Green Cross Cell Corporation

Treatments:

Dacarbazine
Temozolomide